Untitled

Woltering, Eugene A.; Bergsland, Emily K.; Beyer, David T.; O’Dorisio, Thomas M.; Rindi, Guido; Klimstra, David S.; Tang, Laura H.; Reidy‐Lagunes, Diane; Strosberg, Jonathan R.; Wolin, Edward M.; Vinik, Aaron I.; Nakakura, Eric K.; Asare, Elliot A.; Bushnell, David; Schilsky, Richard L.; Wang, Yi-Zarn; Kim, Michelle K.; Liu, Eric H.; Jensen, Robert T.; Wong, Rebecca; Ramage, John; Mallin, Katherine; Pommier, Rodney F.; Amin, Mahul B.; Edge, Stephen B.; Greene, Frederick L.; Byrd, David R.; Brookland, Robert K.; Washington, Mary Kay; Gershenwald, Jeffrey E.; Compton, Carolyn C.; Hess, Kenneth R.; Sullivan, Daniel C.; Jessup, J. Milburn; Brierley, James D.; Gaspar, Lauri E.; Balch, Charles M.; Winchester, David P.; Madera, Martin; Gress, Donna M.; Meyer, Laura

doi:10.1007/978-3-319-40618-3_31

Cited by 16 publications

(40 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Laskaratos et al showed that mesenteric lymphadenopathy was associated with short OS, but the definition of lymphadenopathy was unclear. The latest AJCC TNM staging (8th edition) newly defined LMM >2 cm as N2 . This definition was intended for prospective collection of data of mesenteric mass size for future validation, as the cutoff point was not supported by robust evidence.…”

Section: Discussionmentioning

confidence: 99%

“…LMM was defined as a mesenteric mass >2 cm on preoperative contrast‐enhanced computed tomography or magnetic resonance imaging. The cutoff point of the size was in accordance with the definition of N2 in the latest AJCC TNM staging . Extent of liver involvement was evaluated on preoperative imaging as absent, <25%, 25% to 50%, and ≥50%, as previously described .…”

Section: Methodsmentioning

confidence: 99%

“…11,[14][15][16][17][18][19] The latest American Joint Committee on Cancer (AJCC) TNM staging for NETs of the jejunum and ileum (8th edition) defined a new category of N2 as a large mesenteric mass (LMM) >2 cm, 12 or more positive nodes, or involving the main superior mesenteric vessels. 20 While liver metastasis is a well-established prognostic factor, the prognostic significance of LMM is ill-defined. 8,11,21,22 Therefore, in this study, we evaluated whether the LMM is prognostic for patients with i-NETs.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors

Kasai

Mahuron

Hirose

et al. 2019

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

Background and Objectives Ileal neuroendocrine tumors (i‐NETs) frequently metastasize to mesenteric lymph nodes and the liver. Regional lymphadenopathy is associated with desmoplasia of the mesentery forming a large mesenteric mass (LMM). Although the latest American Joint Committee on Cancer TNM staging (8th edition) defined LMM >2 cm as N2, the prognostic impact of LMM is ill‐defined. We evaluated whether LMM is prognostic for patients with i‐NETs. Methods This single‐institution, retrospective cohort study included 106 patients who underwent resection of i‐NETs between 2007 and 2018. Overall survival (OS) and liver progression‐free survival (LPFS) were compared between patients with and without LMM. Results LMM was present in 66 patients (62%) and was not associated with the presence or absence of liver metastasis (P = .969) or the extent of liver involvement (P = .938). OS and LPFS differed significantly between patients with and without LMM (5‐year OS rates of 64.8% and 92.9%, respectively, P = .011; 3‐year LPFS rates of 45.3% and 67.5%, respectively, P = .025). In multivariate analysis, LMM was an independent prognostic factor for both OS (hazard ratio: 4.69, 95% confidence interval: 1.63‐17.6) and LPFS (1.99, 1.08‐3.88). Conclusion LMM >2 cm is prognostic for OS and LPFS and represents aggressive tumor biology.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Prognostic impact of a large mesenteric mass >2 cm in ileal neuroendocrine tumors

Kasai

Mahuron

Hirose

et al. 2019

Journal of Surgical Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Small‐intestine neuroendocrine tumours (NETs) are the most commonly encountered malignant neoplasms of the small intestine, with an incidence of five per 100 000 . They are frequently associated with lymph node metastasis and mesenteric tumour deposits (MTDs), both of which alter the overall stage in the 8th edition of the American Joint Committee on Cancer (AJCC) staging system for small‐intestine NETs . MTDs are defined as discrete but irregular mesenteric tumour nodules discontinuous from the primary neoplasm; they are associated with frequent liver metastasis and a poor prognosis .…”

Section: Introductionmentioning

confidence: 99%

“…1,2 They are frequently associated with lymph node metastasis and mesenteric tumour deposits (MTDs), both of which alter the overall stage in the 8th edition of the American Joint Committee on Cancer (AJCC) staging system for small-intestine NETs. [3][4][5] MTDs are defined as discrete but irregular mesenteric tumour nodules discontinuous from the primary neoplasm; they are associated with frequent liver metastasis and a poor prognosis. 5,6 In addition, MTDs are frequently associated with dense fibrosis, which can lead to entrapment of adjacent large mesenteric vessels and nerves.…”

Section: Introductionmentioning

confidence: 99%